Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Share:

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2024, Vol. 29 ›› Issue (1): 114-120.doi: 10.12092/j.issn.1009-2501.2024.01.013

Previous Articles    

Advances in the study of mesenchymal stem cells in obstructive sleep apnea hypoventilation syndrome

XU Jinhui1, YUE Hongmei1,2, LI Yating1, LIU Miaomiao1, WU Xingdong1, ZHU Haobin1   

  1. 1 The First Clinical College of Medicine, Lanzhou University, Lanzhou 730000, Gansu, China; 2 Department of Respiratory and Critical Care Medicine, The First Hospital of Lanzhou University, Lanzhou 730000, Gansu, China
  • Received:2023-07-17 Revised:2023-08-30 Online:2024-01-26 Published:2024-01-15

Abstract:

Mesenchymal stem cells (MSCs) are self-regenerating, rapidly proliferating pluripotent stem cells that depend primarily on their derived pro-angiogenic, inflammatory regulatory, and trophic factors to exert beneficial effects that attenuate deleterious inflammatory responses, reduce vascular damage, and promote tissue repair and regeneration. Obstructive sleep apnea hypoventilation syndrome (OSAHS) is a chronic disorder marked by oropharyngeal collapse during sleep, resulting in transient reduced airflow, large fluctuations in intrathoracic pressure, and intermittent hypoxia and hypercapnia. OSAHS subsequently cytokine-mediated inflammatory cascades, oxidative stress, and ischemia, recruit MSCs from inflamed and damaged tissues through MSCs-derived of anti-inflammatory and pro-angiogenic factor activity, reduce hypoxia, suppress inflammation, promote regeneration, and prevent fibrosis in OSAHS-injured tissues. In this paper, we will describe the pathogenesis of inflammation, oxidative stress, fibrosis and ischemia from the perspective of OSAHS, highlighting the current research progress on MSCs-dependent regulation of OSAHS-related pathology.

Key words: obstructive sleep apnea hypoventilation syndrome, mesenchymal stem cells, mechanism of action, research progress

CLC Number: